Pliant Therapeutics Inc (PLRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.16+2.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PLRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 160.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PLRX — director transition
Dated 2026-07-13
Director — Robert Iannone, M.D., M.S.C.E. and Flavia Borellini, Ph.D.: The Board of Directors appointed two new directors to fill newly-created vacancies and expanded their roles within the company.
Why it matters: Progress in clinical programs is key for future growth and investor confidence.
Supportive ifManagement announces a new clinical trial or shares good results from a trial.
Worry ifManagement delays or cancels a key clinical trial.
Why it matters: New partnerships or acquisitions can help growth. They can also improve market position.
Supportive ifA new partnership or acquisition worth more than $50M is announced.
Worry ifThere are no announcements of partnerships or acquisitions in the next quarter.
Why it matters: More cuts will show how well Pliant manages its costs.
Supportive ifOperating costs drop more from $21.8 million in Q1 2026.
Worry ifOperating costs go up or stay the same without more cuts.
Why it matters: Monitoring cash reserves is key to understanding if Pliant can fund operations through 2028. A drop could signal financial strain.
Worry ifCash reserves stay above $150 million, showing strong financial health.
Less concerning ifCash reserves fall below $150 million. This raises worries about paying for operations.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$172 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $332 loss on $10,000 · 3.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,345 loss on $10,000 · 13.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New data presented at AACR could validate PLN-101095's potential as a novel treatment.
Supportive ifGood results from more trials or studies were shared at AACR 2027.
Worry ifNegative results or lack of new data presented at AACR 2027.
Why it matters: How Pliant's peers do can affect investor feelings and market position.
Watch forPeer companies like LLY or ABBV show strong revenue growth or positive news.
Also watch forPeer companies share bad news or lower revenue growth.
Why it matters: Understanding cash burn is key to assessing if Pliant can fund its operations long-term.
Worry ifCash and equivalents stay steady or grow, showing controlled cash use.
Less concerning ifCash and equivalents drop a lot, showing higher cash use than expected.
Why it matters: Less cash burn shows better financial health and management.
Supportive ifCash from operations is getting better. It is getting closer to breakeven.
Worry ifCash burn worsens or operating losses increase beyond current levels.
Why it matters: Keeping cash reserves is key for funding trials and operations. It affects stability.
Worry ifCash and short-term investments are over $150 million.
Less concerning ifCash reserves are below $150 million. This raises concerns about funding.
Why it matters: A sharp decline in cash reserves could signal financial distress. This would raise concerns about the company's ability to fund operations.
Worry ifCash reserves drop below $150 million in the next quarter.
Less concerning ifCash reserves remain stable or increase in the next quarter.
Why it matters: New presentations may give more proof of PLN-101095's effectiveness and safety. This could affect investor feelings and stock performance.
Supportive ifPliant shares new data on PLN-101095 at a big oncology conference.
Worry ifNo new data or updates on PLN-101095 will be shared at upcoming conferences.
Why it matters: Ongoing cost cuts will show Pliant's skill in managing money. This could help cash flow and investor trust.
Supportive ifOperating costs are down more than last quarter.
Worry ifOperating expenses rise or do not drop as expected.
Why it matters: Interim data will show how well PLN-101095 works in patients with hard-to-treat tumors. Positive results could boost confidence in the drug's potential.
Supportive ifInterim data from the FORTIFY trial shows strong effects against tumors in patients.
Worry ifInterim data shows weak effects against tumors. There are no safety issues.